Larvol Delta - SELLAS-Life-Sciences-Group-Inprovided-an-update-on-the-ongoing-Phase-3-REGAL-trial-evaluating-GPS-as-a-potential-maintenance-therapy-in-patients-with-AML-after-second-complete-remission-CR2

Zeltherva (galinpepimut-S) - SELLAS Life Sciences

https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/default.aspx

Dec 29, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next